Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Jun 28, 2025; 31(24): 108298
Published online Jun 28, 2025. doi: 10.3748/wjg.v31.i24.108298
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart of patient inclusion. MSS: Microsatellite stable; mCRC: Metastatic colorectal cancer; PD-1: Programmed death 1.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 After propensity score-matching analysis of progression-free survival and overall survival. A: After propensity score-matching analysis of progression-free survival (ratio = 4); B: After propensity score-matching analysis of overall survival (ratio = 4).
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Kaplan-Meier curve of original cohort. A: In the original cohort (progression-free survival); B: In the original cohort (overall survival).
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Sensitivity analysis of progression-free survival. A: After propensity score-matching analysis in progression-free survival (PFS) (ratio = 1); B: After propensity score-matching analysis in PFS (ratio = 2); C: After propensity score-matching analysis in PFS (ratio = 2); D: After inverse probability of treatment weighting analysis (PFS).
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Sensitivity analysis of overall survival. A: After propensity score-matching analysis in overall survival (OS) (ratio = 1); B: After propensity score-matching analysis in OS (ratio = 2); C: After propensity score-matching analysis in OS (ratio = 3); D: After inverse probability of treatment weighting analysis (OS).
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Forest plots depict the hazard ratios and 95% confidence intervals for progression-free survival by subgroup. ECOG: Eastern Cooperative Oncology Group; HR: Hazard ratio; CI: Confidence interval.
Figure 7
Open in New Tab Full Size Figure Download Figure
Figure 7 Lactate dehydrogenase as a predictive biomarker of progression-free survival. A: Receiver operating characteristic curves of lactate dehydrogenase (LDH) at 9 months, 12 months, and 15 months before patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy; B: Survival curves of LDH before patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy (high group: LDH ≥ 199 mmol/L and low group LDH < 199 mmol/L). AUC: Area under the curve.